Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01709032
Recruitment Status :
First Posted : October 17, 2012
Results First Posted : March 6, 2019
Last Update Posted : March 6, 2019
Children's Hospital of Philadelphia
The Cooley’s Anemia Foundation,
Ann & Robert H Lurie Children's Hospital of Chicago
We hypothesize that the combination treatment with deferasirox and deferiprone will be well tolerated and will result in significant improvement in cardiac and liver iron levels.
Condition or disease
Thalassemia Major With Severe Transfusional Iron Overload
Drug: Deferasirox and deferiprone
Phase 1Phase 2
Death and disability from iron related damage to the heart remain the most serious issue facing transfusion-dependent patients with thalassemia. However, over the past decade there have been several reports of improved survival and fewer cardiac complications. This improvement may be related to the availability of three chelators and also the accurate measurement of iron stores in various organs (e.g. heart and liver) with magnetic resonance imaging, which allows for personalized, tailored medical care for patients. The chelator characteristics, side effect profiles, and ability to remove iron from specific organs differ among the chelators, suggesting that combination therapy may be beneficial. Using two drugs at lower doses may be more tolerable than escalating doses of a single drug and may improve iron removal. The combination of deferoxamine and deferiprone has been shown to be particularly beneficial for reducing cardiac iron, but it requires a painful injection/infusion, which hinders adherence. This pilot study aims to investigate the safety of an oral-only combination chelator regimen (deferasirox and deferiprone) in individuals with thalassemia major with poorly controlled iron overload and to assess how well this chelator combination lowers iron stores over one year.
Number of Participants With Improvement in Liver Iron Concentration [ Time Frame: 12 months ]
Determine the safety of the combination of Deferasirox and Deferiprone for the treatment of subjects with Thalassemia Major and Severe Iron Overload by assessing change in liver iron concentration from baseline to follow-up
Secondary Outcome Measures :
Number of Participants With Improvement in Cardiac T2* MRI [ Time Frame: 12 months ]
Improvement in Cardiac T2* MRI from baseline to determine if there is a reduction of cardiac iron burden.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Alpha or beta thalassemia
Receiving chronic transfusions (at least 20 transfusions in lifetime) with iron overload requiring treatment with chelation
Serum ferritin >500 ng/ml
Liver iron concentration equal to or greater than 10 mg/g dw (by R2 MRI) or 7 to 10 mg/g dw (by R2 MRI) and not improving OR cardiac T2* between 6 and <20 ms
Women of childbearing age must have a negative pregnancy test
Agree to use approved method of contraception for the duration of the study
Subjects must have a good understanding of the study and be willing to comply with study procedures
Subjects with past history of unexplained neutropenia (ANC < 1500/mcL), clinically significant renal disease (creatinine above the upper limit of normal), proteinuria >300 mg/L, clinically significant liver disease (ALT > 5x upper limit of normal), pulmonary or cardiovascular disease
History of other clinically relevant oral, endocrine, neurologic, psychiatric, immunologic, bone marrow or skin disorder that contraindicates dosing with deferasirox or deferiprone
History of adverse reaction or known allergy to either deferasirox or deferiprone necessitating drug discontinuation
Currently receiving treatment for active hepatitis
Use of any investigational agent in the past 30 days
Cardiac T2* <6 ms, left ventricular ejection fraction < 56%, and/or arrhythmia (certain subjects may be eligible if they have already had a trial of deferoxamine and deferiprone). Subjects who refuse to use deferoxamine after extensive consultation with at least 2 health care providers will also be allowed to participate.
Pregnant or breastfeeding females
Unwilling or unable to comply with study related procedures